xiv threats. However, nothing has demonstrated our collective vulnerability to pathogenic infection more than the West African outbreak of Ebola which showed the world the devastating effects of a lethal infection. Although ultimately controlled by effective infection prevention, this outbreak reminded us of the continued importance of understanding, preventing and treating infectious diseases.
It is against this background that we have prepared this fourth edition of Infectious Diseases. In doing this we have been conscious not only of the extraordinary developments in the science and practice of infection, but also in the evolving needs of our readers. Scientists and practitioners turn to books like this both for specific information on unfamiliar subjects but also as a source for further education and training. Mindful of this, we have introduced a variety of exciting new elements to the book. Alongside our widely acclaimed Practice Points offering pithy, practical advice on common management problems we have now added several new features designed to assist our readers. These include online mannequins providing a ready reference to pharmacokinetic data on antimicrobial agents, which are traditionally difficult to access in an easily useful form, and also a portfolio of online multiple choice questions, fully supported by reference material, as a resource for postgraduate education. We are grateful to our two new Associate Editors in Medical Education, Bethany Davies and Courtney Chrisler, for their help with this important new addition to the book. As ever, we are indebted to the extraordinary commitment and expertise of our Section Editor colleagues and to the very many expert contributors who have so graciously agreed to undertake comprehensive revision of their chapters from the previous edition, and, in many cases, write completely new chapters. We also wish to express our profound thanks to the team at Elsevier who have cajoled, supported and encouraged us to get this done, in particular Sharon Nash, Jo Souch and Belinda Kuhn, and last but by no means least, we thank the Section Editors from the previous edition, Jack Sobel, Roger Finch, Scott Hammer, Tim Kiehn and Keith McAdam, without whom we would never have been in a position to prepare this new edition of the book. We hope that you, the reader, will find what you are looking for and we welcome feedback on how we can continue to improve Infectious Diseases.
Jon Cohen William Powderly Steven Opal
We live in interesting times. The discipline of infectious diseases has rarely faced so much promise, and yet such peril. The possibility of an AIDS-free world within the next generation is now seriously contemplated, based on the intelligent use of combinations of antiretroviral agents and selected use of pre-exposure prophylaxis, and even without the benefit of a vaccine that induces sterilizing immunity against human immunodeficiency virus (HIV). This would not have seemed possible even 25 years ago. Similarly, the remarkable success story of possibly curing hepatitis C virus (HCV) with safe, oral, directly acting, antiviral agents is now well within our grasp. Only 30 years ago the cause of non-A non-B post-transfusion hepatitis was unknown and no serologic test was available to detect carriers and prevent transmission.
Real progress in developing a multistage malaria vaccine has recently been made, and a vaccine for dengue is on the horizon. Promising and innovative vaccine strategies using reverse genetic approaches are now in development, targeting recalcitrant bacterial, fungal and parasitic pathogens. Rapid molecular diagnostics are finally making huge inroads in the clinical microbiology laboratory. Such advances are essential if we are to be able to make accurate diagnoses within hours and provide optimal care for our patients in this era of precision medicine.
Yet despite these advances, we are constantly reminded of just how fragile our dominion over the microbial world really is. The human population has swelled to over 7 billion inhabitants; most now reside in crowded cities, often without the benefits of adequate sanitation or reliable nutrition. As Paul Farmer has written, physicians 'need to think hard about poverty and inequality, which influence any population's morbidity and mortality' , and this is no more so than in the case of infectious diseases. The global spread of antimicrobial resistance now poses the very real threat of infection for which there are no effective treatments. Novel resistance mechanisms in gram-negative bacteria have emerged and spread rapidly across the world, challenging the foundations of the modern era of medicine. Drug-resistant tuberculosis, including infection with organisms that are extensively resistant (XDR-TB), continues to challenge global efforts at control. Despite the extensive efforts to provide global access to antiretroviral therapy, new cases of HIV continue in epidemic numbers, and many continue to die from AIDS. The spread of vector-borne pathogens, especially dengue, chikungunya and Zika, continues and corona virus-related Middle Eastern respiratory syndrome has emerged as yet another unexpected challenge. Zika-induced microcephaly is hugely important and clearly demonstrates our continued vulnerability to new microbial PREFACE TO THE FOURTH EDITION
